Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2020; 58(05): 476-477DOI: 10.1055/a-1159-8203 Mitteilungen der DGVS Arzneimittelnebenwirkungen in der Gastroenterologie Recommend Article Abstract Buy Article Full Text References Literatur 1 Preiß JC. et al. Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014. Z Gastroenterol 2014; 52: 1431-1484 2 Kucharzik T. et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2018; 56: 1087-1169 3 Cuffari C, Theoret Y, Latour S. et al. 6-mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996; 9: 401-406 4 Dubinsky MC. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713 5 Dubinsky MC. et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915 6 Chapdelaine et al. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases. Clin Rheumatol 2017; 36: 1341-1348 7 Moreau et al. Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Ther Adv Gastroenterol 2017; 10: 819-827 8 Hoentjen et al. Safety and Effectiveness of Long-term Allopurinol – Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2013; 19: 363
